Lisocabtagene Maraleucel Shows Deep, Durable Responses in Patients with Relapsed or Refractory MZL After at Least Two Previous Lines of Systemic Therapy By Ogkologos - February 19, 2026 128 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the marginal zone lymphoma cohort of the TRANSCEND FL study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR ASCO20 Virtual Research Round Up Podcast: Leukemia, Colorectal Cancer, and Lung... June 23, 2020 Gene Tied to Alzheimer’s May Be Associated with Cancer-Related Cognitive Problems November 9, 2018 Young Mom With Metastatic Breast Cancer Travels To Mexico For Alternative... November 26, 2019 When Ovarian Cancer Returns, Surgery May Be a Good Choice for... January 12, 2022 Load more HOT NEWS Catch-Up HPV Testing May Help Prevent Cervical Cancer in Some Over... Adding Pembrolizumab to Standard Chemotherapy, Followed by Pembrolizumab Maintenance, Results in... Can we grow the treatments of tomorrow? – That Cancer Conversation Empowering People With Cancer: A Q&A With Cancer.Net Editor in Chief...
